Daniel Gerlach (@gerlach_d) 's Twitter Profile
Daniel Gerlach

@gerlach_d

Associate Scientific Director, Computational Biology Oncology at @boehringer ๐Ÿงฌ Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.

ID: 1325200380

linkhttps://www.linkedin.com/in/daniel-gerlach calendar_today03-04-2013 18:40:12

8,8K Tweet

1,1K Followers

505 Following

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscoverโ€ฆ

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD

Always great to hear the original RAScal <a href="/cjder23/">Channing Der</a> <a href="/derlabunc/">Der Lab at UNC</a> talk about KRAS &amp; KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) &amp; 160 clinical trials. Absolutely amazing. 
<a href="/DavidHongMD/">David S. Hong MD</a>
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

#ELCC25 Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: - ORR 38% - mPFS 9.8m, mDOR 15.1m - modest tox (diarrhea & rash) - 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to ๐Ÿ‡ฎ๐Ÿ‡ช ESMO - Eur. Oncology CancerTrialsIreland ๐ŸŒˆ @Oncoalert #LCSM

#ELCC25 
Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC:

- ORR 38%
- mPFS 9.8m, mDOR 15.1m
- modest tox (diarrhea &amp; rash)
- 200mg dose selected for ph III

Promising. Delighted Ph III RASolve trial of this agent, coming to ๐Ÿ‡ฎ๐Ÿ‡ช 
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/cancertrials_ie/">CancerTrialsIreland ๐ŸŒˆ</a> @Oncoalert #LCSM
Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/acโ€ฆ

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd) | Nature Communications idp.nature.com/authorize?respโ€ฆ

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/pโ€ฆ

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats <a href="/curijoey/">G Curigliano MD PhD</a> for leading the DB06 trial that backed this approval!
astrazeneca.com/media-centre/pโ€ฆ
EMBL Events (@emblevents) 's Twitter Profile Photo

๐Ÿงฌ๐Ÿ’ก The EMBL Conference 'Cancer genomics' is now open for registration! Submit your abstract by 13 July and join the community of leading scientists and academic clinicians working on cancer genomics ๐Ÿ‘ฉ๐Ÿพโ€๐Ÿ”ฌ๐Ÿ‘จ๐Ÿปโ€๐Ÿ”ฌ #EMBLCanGen ๐Ÿ—“๏ธ 11 โ€“ 14 November 2025 ๐Ÿ“ EMBL Heidelberg and Virtual

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157โ€ฆ

Evolution of HER2 testing over 40 yrs.

IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging.

We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25.

Stay tuned.

nature.com/articles/s4157โ€ฆ
Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

โญ๏ธWith so many KRAS targeted drugs entering clinical trials pleased to share our editorial ๐Ÿ‘‰๐ŸผReady, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer ๐Ÿš€๐Ÿงฌ๐ŸŽฏ | JCO Oncology Practice JCO Oncology Practice ASCO OncoDaily ascopubs.org/doi/full/10.12โ€ฆ

Emil Lou, MD, PhD, FACP (@cancerassassin1) 's Twitter Profile Photo

The 2025 AACR Annual Meeting is coming up in a few short weeks. This post from the AACR details What to Know Before Heading to #AACR25 taking place in #Chicago April 25-30, 2025: aacr.org/blog/2025/04/0โ€ฆ

The 2025 <a href="/AACR/">AACR</a> Annual Meeting is coming up in a few short weeks. This post from the AACR details What to Know Before Heading to #AACR25 taking place in #Chicago April 25-30, 2025:

aacr.org/blog/2025/04/0โ€ฆ
Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors | Molecular Cancer Therapeutics | American Association for Cancer Research aacrjournals.org/mct/article/24โ€ฆ

Nature Reviews Drug Discovery (@natrevdrugdisc) 's Twitter Profile Photo

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h
Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer
Emil Lou, MD, PhD, FACP (@cancerassassin1) 's Twitter Profile Photo

The AACR is on #Bluesky, where a lot of the online rigorous and respectful scientific discourse has taken place and grown since November. A lot more to come during the upcoming 2025 AACR Annual Meeting (#AACR25) April 25-30. @theaacr.bsky.social

The <a href="/AACR/">AACR</a> is on #Bluesky, where a lot of the online rigorous and respectful scientific discourse has taken place and grown since November. A lot more to come during the upcoming 2025 AACR Annual Meeting (#AACR25) April 25-30.  @theaacr.bsky.social
Bruce Levine, Ph.D. ๐Ÿ‡บ๐Ÿ‡ฆ๐Ÿฅผ๐Ÿ”ฌ๐Ÿงฌ๐Ÿงช๐Ÿ’‰ (@bllphd) 's Twitter Profile Photo

Drug Development Is Slowing Down After Cuts at the #FDA Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials ~3,500 workers were cut at the FDA, including Chief Medical Officer Dr. Hilary Marston and Dr. Peter Stein, who

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Emerging importance of HER3 in tumorigenesis and cancer therapy | Nature Reviews Clinical Oncology nature.com/articles/s4157โ€ฆ

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

I know #AACR25 is coming up, but the program and roster for AACR Special Conference on #PancreaticCancer in Boston in the fall of 2025 is also up and available.... the attendance at this just keeps growing! Dr. Edna Cukierman, Ph.D. Laura DeLong Wood aacr.org/meeting/aacr-sโ€ฆ